GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » Piotroski F-Score

Codiak BioSciences (Codiak BioSciences) Piotroski F-Score : 0 (As of May. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Codiak BioSciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Codiak BioSciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Codiak BioSciences's Piotroski F-Score or its related term are showing as below:


Codiak BioSciences Piotroski F-Score Historical Data

The historical data trend for Codiak BioSciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codiak BioSciences Piotroski F-Score Chart

Codiak BioSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
N/A N/A N/A 3.00

Codiak BioSciences Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 3.00 N/A 3.00 2.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Net Income was 16.662 + -8.028 + -6.775 + -19.278 = $-17.42 Mil.
Cash Flow from Operations was -21.522 + -20.851 + -14.597 + -10.11 = $-67.08 Mil.
Revenue was 7.697 + 12.704 + 13.145 + 0.028 = $33.57 Mil.
Gross Profit was 7.697 + 12.704 + 13.145 + 0.028 = $33.57 Mil.
Average Total Assets from the begining of this year (Sep21)
to the end of this year (Sep22) was
(158.725 + 171.67 + 150.07 + 132.71 + 134.396) / 5 = $149.5142 Mil.
Total Assets at the begining of this year (Sep21) was $158.73 Mil.
Long-Term Debt & Capital Lease Obligation was $58.27 Mil.
Total Current Assets was $61.23 Mil.
Total Current Liabilities was $14.46 Mil.
Net Income was -17.957 + -10.308 + -21.809 + -21.702 = $-71.78 Mil.

Revenue was 1.64 + 13.191 + 0.89 + 1.157 = $16.88 Mil.
Gross Profit was 1.64 + 13.191 + 0.89 + 1.157 = $16.88 Mil.
Average Total Assets from the begining of last year (Sep20)
to the end of last year (Sep21) was
(110.351 + 151.341 + 191.499 + 175.274 + 158.725) / 5 = $157.438 Mil.
Total Assets at the begining of last year (Sep20) was $110.35 Mil.
Long-Term Debt & Capital Lease Obligation was $60.02 Mil.
Total Current Assets was $103.91 Mil.
Total Current Liabilities was $23.10 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Codiak BioSciences's current Net Income (TTM) was -17.42. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Codiak BioSciences's current Cash Flow from Operations (TTM) was -67.08. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep21)
=-17.419/158.725
=-0.10974327

ROA (Last Year)=Net Income/Total Assets (Sep20)
=-71.776/110.351
=-0.65043362

Codiak BioSciences's return on assets of this year was -0.10974327. Codiak BioSciences's return on assets of last year was -0.65043362. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Codiak BioSciences's current Net Income (TTM) was -17.42. Codiak BioSciences's current Cash Flow from Operations (TTM) was -67.08. ==> -67.08 <= -17.42 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=58.266/149.5142
=0.38970212

Gearing (Last Year: Sep21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep20 to Sep21
=60.016/157.438
=0.38120403

Codiak BioSciences's gearing of this year was 0.38970212. Codiak BioSciences's gearing of last year was 0.38120403. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep22)=Total Current Assets/Total Current Liabilities
=61.233/14.456
=4.23581904

Current Ratio (Last Year: Sep21)=Total Current Assets/Total Current Liabilities
=103.913/23.103
=4.49781414

Codiak BioSciences's current ratio of this year was 4.23581904. Codiak BioSciences's current ratio of last year was 4.49781414. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Codiak BioSciences's number of shares in issue this year was 25.16. Codiak BioSciences's number of shares in issue last year was 22.325. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=33.574/33.574
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=16.878/16.878
=1

Codiak BioSciences's gross margin of this year was 1. Codiak BioSciences's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep21)
=33.574/158.725
=0.21152307

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep20)
=16.878/110.351
=0.15294832

Codiak BioSciences's asset turnover of this year was 0.21152307. Codiak BioSciences's asset turnover of last year was 0.15294832. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+0+0+0+1
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Codiak BioSciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Codiak BioSciences  (OTCPK:CDAKQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Codiak BioSciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Codiak BioSciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Codiak BioSciences (Codiak BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
35 Cambridge Park Drive, Suite 500, Cambridge, MA, USA, 02140
Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.
Executives
Yalonda Howze officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Sriram Sathyanarayanan officer: Chief Scientific Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Nicole Barna officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Douglas E Williams director, officer: President & CEO C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Linda Bain officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Konstantin Konstantinov officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Arundathy N. Pandite director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Benny Sorensen officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Anne-virginie Eggimann director C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Jennifer J. Wheler officer: Chief Medical Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Alaska Permanent Fund Corp 10 percent owner 801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142

Codiak BioSciences (Codiak BioSciences) Headlines